Kura Oncology, Inc. (KURA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Verve Therapeutics, Inc.

Adaptive Biotechnologies Corp.

ADMA Biologics, Inc.

Kura Oncology, Inc.

Novavax, Inc.

Inhibrx, Inc.

Kymera Therapeutics, Inc.

Apogee Therapeutics, Inc.

Sana Biotechnology, Inc.

Cassava Sciences, Inc.

Axcella Health, Inc.

Why is Kura Oncology, Inc. ?

Flat results in Jun 25

ROCE(HY) Lowest at -51.11%
OPERATING PROFIT(Q) Lowest at USD -72.44 MM
PRE-TAX PROFIT(Q) Lowest at USD -66.12 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 5.84%, its profits have fallen by -8.2%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -0.74% over the previous quarter and currently hold 15.13% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kura Oncology, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Kura Oncology, Inc.

7.25%

-0.76

58.68%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

142.74%

EBIT Growth (5y)

-196.02%

EBIT to Interest (avg)

-124.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.77

Sales to Capital Employed (avg)

0.19

Tax Ratio

1.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.60

EV to EBIT

0.31

EV to EBITDA

0.32

EV to Capital Employed

0.23

EV to Sales

-0.94

PEG Ratio

Dividend Yield

ROCE (Latest)

72.06%

ROE (Latest)

-49.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 124.98 MM

NET PROFIT(HY)

Higher at USD -123.55 MM

RAW MATERIAL COST(Y)

Fallen by -9,853% (YoY

NET SALES(9M)

Higher at USD 83.28 MM

CASH AND EQV(HY)

Highest at USD 1,288.92 MM

DEBT-EQUITY RATIO (HY)

Lowest at -200.09 %

DEBTORS TURNOVER RATIO(HY)

Highest at 20.38 times

-8What is not working for the Company

ROCE(HY)

Lowest at -51.11%

OPERATING PROFIT(Q)

Lowest at USD -72.44 MM

PRE-TAX PROFIT(Q)

Lowest at USD -66.12 MM

NET PROFIT(Q)

Lowest at USD -66.12 MM

EPS(Q)

Lowest at USD -0.75

Here's what is working for Kura Oncology, Inc.

Net Sales

At USD 83.28 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD 124.98 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv

Highest at USD 1,288.92 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -200.09 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 20.38 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

Higher at USD 83.28 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Raw Material Cost

Fallen by -9,853% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Kura Oncology, Inc.

Operating Profit

Lowest at USD -72.44 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -66.12 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

Fallen at -30.07%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -66.12 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit

Fallen at -30.07%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.75

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)